

***Chitinophaga terrae* Bacteremia in Human**

To the Editor: The genus *Chitinophaga*, first described by Sangkhobol and Skerman in 1981, belongs to the phylum Bacteroidetes (formerly the *Cytophaga-Flexibacter-Bacteroides* group), which includes filamentous, chitinolytic, gliding bacteria that transform into spherical bodies upon aging (1). This genus contains 10 environmental species that demonstrate similarities in 16S rDNA sequence and in phenotypic and chemotaxonomic data (menaquinone, fatty acids, hydroxy fatty acid, and polyamine) (2–5). *Chitinophaga terrae*, originally isolated from soil in South Korea, was first described in 2007 (3,4). Here we report a case of bacteremia due to *C. terrae* in a severely immunosuppressed woman.

On July 31, 2008, a 51-year-old woman was admitted to the emergency department at Nantes University Hospital in Nantes, France, because of a slowly growing left cheek mass associated with weight loss and change of general state. Physical examination showed several cutaneous infiltrated nodules, bilateral axillary adenopathies, and hepatosplenomegaly. Deteriorating renal function led to intermittent hemodialysis. Histopathology of skin and renal biopsies revealed a diffuse, high-grade, large B-cell lymphoma with cutaneous localization. Systemic CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and methotrexate intrathecal chemotherapy were begun August 9. She developed bone marrow aplasia 3 days later, shortly followed by the onset of pyrexia. *Corynebacterium pseudotuberculosis* was isolated from 3 blood samples, 2 drawn using the central venous catheter (CVC) and 1 from peripheral blood. Consecutively, serotype O1 *Pseudomonas aeruginosa* strain was isolated from cultures

of urine and fecal specimens. The empirical antimicrobial drug treatment started with piperacillin-tazobactam, ciprofloxacin, and teicoplanin on August 16 and was replaced by imipenem, ciprofloxacin, and teicoplanin on August 21. On August 26, the patient was admitted to the medical intensive care unit (MICU) after indications of toxic epidermal necrolysis. Blood analysis showed pancytopenia with thrombocytopenia ($26 \times 10^9/L$), anemia (hemoglobin 8.7 g/dL), and profound leukopenia ($0.01 \times 10^9/L$). Antimicrobial drug treatment was changed to an association of noncytotoxic drugs, i.e., aztreonam, amikacin, and teicoplanin. Despite this broad-spectrum antimicrobial therapy, 4 aerobic blood cultures (1 drawn August 29, 2 on September 2, and 1 on September 3), 2 drawn using the CVC and 2 from a peripheral site, yielded gram-negative bacilli (our laboratory reference no. NTS8639) after 2 days' incubation. The CVC was removed September 3 and sent to the laboratory for culture. The catheter tip was immersed in 2 mL of brain heart infusion agar, and semiquantitative culture was performed on the blood agar plate using 100 μ L of the solution. The culture remained negative.

On September 2, treatment was changed to imipenem, trimethoprim-sulfamethoxazole, and teicoplanin. Additionally, diagnosis of invasive pulmonary aspergillosis led to changing caspofungin prophylaxis to voriconazole. Trimethoprim-sulfamethoxazole treatment was stopped September 9, and imipenem was stopped September 25, a week after bone marrow recovery. The patient was discharged from MICU on October 7.

Yellow-pigmented colonies grew on bromocresol purple lactose agar plate after 48 hours of incubation at 37°C and appeared as thin gram-negative bacilli after gram-staining was performed. The nonfermenting, nonmotile, oxidase-positive bacterium could grow at various pH values

(pH 6.0, 7.3, and 8.0) and at different temperatures (30, 37, and 40°C). The semi-automatic Api 20NE gallery (bioMérieux, Marcy l'Etoile, France) identified the strain as *Sphingomonas paucimobilis*, whereas the ID-GNB card of the VITEK 2 system (bioMérieux) identified the bacterium as *Sphingobacterium thalpophilum*. The 16S rDNA amplification and sequencing were performed with universal primers 27f and 1378r as previously described (6). The 1366-bp sequence matched that of *C. terrae* with 100% similarity, according to BIBI (Bioinformatic Bacteria Identification, <http://umr5558-sud-str1.univ-lyon1.fr/leb-ibi/lebibi.cgi>) or BLAST (www.ncbi.nlm.nih.gov) analysis. Phylogenetic analysis with either the neighbor-joining or maximum-parsimony algorithm embedded the NTS8639 strain to the genus *Chitinophaga* and the species *C. terrae* (Figure). The biochemical characteristics of the bacterium corresponded to those previously described for *C. terrae* by Kim and Jung (3). The strain reduced nitrate to nitrite, produced N-acetyl- β -glucosamidase, phosphatase, α - and β -galactosidases, α - and β -glucosidases, and assimilated L-arabinose, L-fucose, D-glucose, maltose, D-mannose, D-melibiose, L-rhamnose, sucrose, and salicin with Api 20NE, Api ID32GN (bioMérieux), and ID-GNB biochemical galleries. Unlike *S. paucimobilis*, the strain was positive for nitrate reductase and L-rhamnose. Also, negative reaction for urease and L-fucose assimilation differentiated the strain from *S. thalpophilum*. At the species level, the bacterium grew well at 37°C, unlike *Chitinophaga arvensicola*, and showed positive oxidase reaction and nitrate reduction, unlike *Chitinophaga ginsengisegetis* (2,5).

Disk diffusion tests showed that the bacterium was multiresistant to antimicrobial drugs, including most of the β -lactams, aminoglycosides, fluoroquinolones, colistin, fosfomicin, and tigecyclin. It remained susceptible to amoxicillin-clavulanate,

